Peptide Therapy
Therapeutic use of bioactive peptides to optimize hormones, enhance healing, modulate immunity, and support longevity.
Evidence Summary
Peptide therapy spans a wide evidence spectrum. The most rigorously studied therapeutic peptide is tesamorelin, an FDA-approved growth-hormone-releasing hormone (GHRH) analogue. A 2026 random-effects meta-analysis of five randomized controlled trials (Obesity Research & Clinical Practice) found that, versus placebo, tesamorelin reduced visceral adipose tissue by 27.71 cm2 (95% CI -38.37 to -17.06), lowered hepatic (liver) fat by 4.28 percentage points (95% CI -6.31 to -2.24) and trunk fat by 1.18 kg, while increasing lean body mass by 1.42 kg (95% CI 1.13 to 1.71) — a favorable body-composition shift — without serious adverse events or disruption of glucose control. These findings build on two pivotal 806-patient phase 3 trials (J Clin Endocrinol Metab, 2010) showing roughly a 15% reduction in visceral fat at 26 weeks that was maintained to 52 weeks, alongside about a 108 ng/mL rise in IGF-1 and improved triglycerides; subsequent analyses linked visceral-fat reduction to improved liver enzymes and metabolic markers. Importantly, this high-quality evidence comes from a specific approved indication (HIV-associated lipodystrophy); use for general longevity or body-composition goals is off-label and investigational. Many popular compounded peptides — including BPC-157 and TB-500 — have encouraging preclinical (mostly animal) data but little or no rigorous human trial evidence, and their regulatory and manufacturing status remains in flux. Source quality and physician supervision are essential. Educational information, not medical advice.
Evidence Scale
Mechanism of Action
Therapeutic peptides are short amino-acid chains that act as signaling molecules — as secretagogues, growth factors, or modulators of inflammation and repair. Growth-hormone-axis peptides such as tesamorelin (a GHRH analogue) and GHRH/GHRP combinations stimulate the pituitary to release growth hormone in a more pulsatile, physiologic pattern, raising IGF-1 and preferentially mobilizing visceral fat while supporting lean mass. Other peptides are proposed to promote tissue repair, immune modulation, or metabolic signaling, though rigorous human evidence for many of these remains limited.
Who Is This For?
Tissue healing, GH optimization, cognitive enhancement, immune modulation. Individual peptide indications vary.
Protocol & Dosing
Dose
Varies by peptide. BPC-157: 250-500mcg daily. CJC/Ipamorelin: 100-300mcg each.
Frequency
Daily to 5 days/week
Duration
Cycles of 4-12 weeks
Protocol Summary
Administration varies by peptide (subcutaneous injection, oral, or nasal) and is typically cycled. Appropriate candidate selection, pharmacy-grade sourcing, baseline and follow-up labs (including IGF-1 where GH-axis peptides are used), and physician supervision are essential. Dosing and duration are peptide-specific.
Latest Evidence
2026: five-trial meta-analysis of tesamorelin, the best-evidenced peptide
Peptide therapy covers a broad evidence spectrum, and the strongest data belong to tesamorelin — an FDA-approved growth-hormone-releasing hormone (GHRH) analogue. A 2026 random-effects meta-analysis pooling five randomized controlled trials found that, compared with placebo, tesamorelin reduced visceral adipose tissue by about 28 cm² and liver fat by about 4 percentage points while adding roughly 1.4 kg of lean body mass — losing harmful fat while preserving muscle, a pattern most weight-loss approaches do not achieve. Earlier 806-patient phase 3 trials showed a ~15% visceral-fat reduction sustained to one year, with higher IGF-1 and improved triglycerides, and no clinically meaningful change in glucose control.
This high-quality evidence comes from one approved indication (HIV-associated lipodystrophy); use for general longevity or body composition is off-label and investigational. Many popular compounded peptides, such as BPC-157 and TB-500, have mostly preclinical (animal) data and limited human evidence, with an evolving regulatory and sourcing landscape. Pharmacy quality, candidacy screening, and physician supervision are essential. Educational information, not medical advice.
2026 META-ANALYSIS · 5 RANDOMIZED TRIALS
Tesamorelin vs placebo: body-composition change
Pooled mean difference vs placebo (kg), 95% CI
- Visceral fat
- −27.71 cm²
- vs placebo · p<0.001
- Liver fat
- −4.28 percentage points
- vs placebo · p<0.001
Related on Peak Human
Growth Hormone Therapy
The GH axis that tesamorelin and GHRH peptides stimulate.
Stem Cell Therapy
A related regenerative approach with a clinical evidence base.
Optimization Service
Physician-supervised, biomarker-tracked optimization at Peak Human.
Longevity
Physician-guided healthy-aging protocols.
Performance
Recovery and body-composition support.
Longevity Research Insider
Weekly review of new longevity research.
What the Human Evidence on BPC-157 Contains
Five small human studies, about 81 people — what they do and don't show.
Key references: Tesamorelin in HIV-associated lipodystrophy: meta-analysis of 5 RCTs — Obes. Res. Clin. Pract. (2026) · Tesamorelin & visceral fat: pooled phase 3 trials (n=806) — J. Clin. Endocrinol. Metab. (2010) · Visceral-fat reduction & metabolic profile — Clin. Infect. Dis. (2012) · Visceral-fat reduction & improved liver enzymes — AIDS (2017)
Interactions & Precautions
Contraindications
- Pregnancy
- Active cancer (for growth-promoting peptides)
- Individual peptide-specific contraindications
Potential Risks
- •Unregulated sources
- •Limited human data for some
- •Regulatory issues
Potential Side Effects
Practitioner Notes
Clinical annotations from Dr. Goel
Tesamorelin is the best-evidenced peptide, with randomized-trial data for visceral-fat reduction in its approved HIV-lipodystrophy indication; its GH-axis mechanism underlies broader interest, but non-approved use is investigational. GHRH/GHRP combinations (e.g., CJC-1295/ipamorelin) are used clinically for GH-axis support with more limited controlled data. For peptides such as BPC-157 and thymosin analogues, human evidence is sparse and sourcing/regulatory status varies — pharmacy quality, careful candidacy screening, baseline and follow-up labs (including IGF-1 for GH-axis peptides), and physician supervision are critical. Avoid growth-promoting peptides in active malignancy and pregnancy. Educational information, not medical advice.
Dr. Sanjeev Goel
Chief Medical Officer, Peak Human
Cost & Access
Cost Range
$$
Accessibility
Availability varies by location
Sample member
Longevity Operator
One number for your longevity journey.
FICO for credit. PHS for longevity. Eight biological domains collapsed into one provable score — intuitive at a glance, rigorous underneath.
- Metabolic
- Hormonal
- Cardiovascular
- Brain / Cognitive
- Sleep
- Musculoskeletal
- Gut
- Immunity / Inflammation
